Table 1.
Neuropeptide transcript differential expression statistics
| Neuropeptide | Cluster | LogFC | F | P | FDR | |||
|---|---|---|---|---|---|---|---|---|
| A-B | D1 | D3 | D4 | |||||
| Carcikinin/ETH | Cluster-5052.1 | 1.18 | 2.31 | 4.4 | 5.9 | 47.91 | 5.42E-11 | 2.63E-06 |
| CHH-2 | Cluster-569.33175 | 2.76 | 0.04 | 1.6 | 3.21 | 7.14 | 0.001 | 0.023 |
| Neuroparsin-3 | Cluster-141,623.0 | −1.27 | 1.68 | −0.32 | 0.14 | 7.03 | 0.001 | 0.024 |
| CFSH | Cluster-126,814.0 | 3.74 | 5.66 | 4.19 | 0.72 | 6.4 | 0.001 | 0.034 |
| CCAP | Cluster-569.9440 | −0.62 | −0.93 | − 0.32 | 0.22 | 6.66 | 0.002 | 0.041 |
| Bursicon-α | Cluster-129,891.0 | −0.57 | −1.17 | − 0.16 | 0.3 | 5.36 | 0.003 | 0.062 |
| Bursicon-β | Cluster-121,462.0 | −0.54 | −1.1 | − 0.07 | 0.21 | 5.02 | 0.005 | 0.076 |
| Allatostatin-CC | Cluster-154,370.0 | −0.35 | − 0.9 | 0.02 | 0.22 | 5.52 | 0.008 | 0.112 |
Differential gene expression analysis statistics for five C. maenas neuropeptides which were differentially expressed across the moult cycle (P < 0.05 and FDR < 0.05, bold font above line) and three non-differentially expressed neuropeptides (P < 0.05 but FDR > 0.05, below line) within the CNS. LogFC are relative to moult stage C3–4. The P-value should be read in conjunction with the false discovery rate (FDR)